Academic freedom in clinical research

被引:56
作者
Nathan, DG [1 ]
Weatherall, DJ
机构
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Oxford, Oxford OX3 9DS, England
关键词
D O I
10.1056/NEJMsb020394
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:1368 / 1371
页数:4
相关论文
共 30 条
[21]   Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major [J].
Olivieri, NF ;
Brittenham, GM ;
McLaren, CE ;
Templeton, DM ;
Cameron, RG ;
McClelland, RA ;
Burt, AD ;
Fleming, KA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (07) :417-423
[22]   IRON-CHELATION THERAPY WITH ORAL DEFERIPRONE IN PATIENTS WITH THALASSEMIA MAJOR [J].
OLIVIERI, NF ;
BRITTENHAM, GM ;
MATSUI, D ;
BERKOVITCH, M ;
BLENDIS, LM ;
CAMERON, RG ;
MCCLELLAND, RA ;
LIU, PP ;
TEMPLETON, DM ;
KOREN, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (14) :918-922
[23]   Oral iron chelation therapy for thalassaemia: An uncertain scene [J].
Pippard, MJ ;
Weatherall, DJ .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) :2-5
[24]   Practical management of iron overload [J].
Porter, JB .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (02) :239-252
[25]  
Rennie D, 1997, JAMA-J AM MED ASSOC, V277, P1762
[26]  
SINGH S, 1992, DRUG METAB DISPOS, V20, P256
[27]   Protein kinases - the major drug targets of the twenty-first century? [J].
Cohen, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315
[28]  
Thompson J., 2001, REPORT COMMITTEE INQ
[29]   Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients [J].
Töndury, P ;
Zimmermann, A ;
Nielsen, P ;
Hirt, A .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (03) :413-415
[30]   PREVENTION OF CARDIAC DISEASE BY SUBCUTANEOUS DEFEROXAMINE IN PATIENTS WITH THALASSEMIA MAJOR [J].
WOLFE, L ;
OLIVIERI, N ;
SALLAN, D ;
COLAN, S ;
ROSE, V ;
PROPPER, R ;
FREEDMAN, MH ;
NATHAN, DG .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (25) :1600-1603